Watch this sneak peek of the AACR Annual Meeting 2018 (www.AACR.org/AM18) to hear AACR President Michael Caligiuri, MD, and Program Committee Chair Elaine Mardis, PhD, discuss some key highlights of the meeting and how you can start preparing today for meeting in Chicago April 14-18, 2018.
This video has been included on the touchONCOLOGY.com website with permission from AACR 2018. For more information about AACR please visit www.aacr.org
Trending Topic
The open-label, single-arm phase Ib/II Felix study (NCT04404660) investigated obecabtagene autoleucel (obe-cel, AUTO1), a novel anti-CD19 autologous CAR-T cell therapy, in adults with relapsed/refractory B-cell acute lymphoblastic leukemia. The results suggest that obe-cel can provide long-term remission without necessarily needing a transplant. touchONCOLOGY spoke with editorial board member, Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA), who summarized the key take-home messages from his presentation at ASCO 2024. Dr Jabbour also discussed the findings from the ASC4FIRST trial (NCT04971226).
The randomized phase III PERSEUS trial (NCT03710603) investigated daratumumab in combination with bortezomib, lenalidomide, and dexamethasone (VRd) compared with VRd and lenalidomide alone in patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). Daratumumab, a CD38 monoclonal antibody, is currently approved ...
Lenalidomide is a standard of care in multiple myeloma. But with the prevalence of the lenalidomide-refractory population increasing, the CARTITUDE-4 trial aimed to assess ciltacabtagene autoleucel for this patient population. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (...
The treatment paradigm for patients with multiple myeloma is very complex. In this touchONCOLOGY interview, we speak with Dr Binod Dhakal (Medical College of Wisconsin, Milwaukee, WI, USA) to break down the treatment paradigm in multiple myeloma, discussing how to ...
ZUMA-23 (NCT05605899) is an on-going phase 3 study investigating axicabtagene ciloleucel (axi-cel) CAR T cell therapy as a first-line therapy in patients with high-risk large B-cell lymphoma. touchONCOLOGY caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer ...
Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved to treat patients with relapsed/refractory large B-cell lymphoma. We caught up with Dr Jason Westin (The University of Texas MD Anderson Cancer Center, Houston, ...
Each year, the EHA Board presents the José Carreras Award to honour leaders in haematological research. touchONCOLOGY caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss his receipt of the José Carreras Award and the key take-home ...
The management of patients with Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL) has evolved over the last few decades, with new and exciting treatments becoming increasingly available. We caught up with Prof Robin Foà (Sapienza University, Rome, Italy) to discuss the ...
The phase III MURANO trial (NCT02005471) reported that venetoclax plus rituximab (venR) resulted in higher progression-free survival and overall survival than bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukaemia. The unmet needs in the treatment of chronic ...
The randomized phase 3 PhALLCON trial was conducted in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. The practice-changing efficacy results and safety data demonstrate a potential for a new standard-of-care therapy for frontline use in this patient population and improvements ...
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with ...
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with ...
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple ...
Keep track of your clinical interests and newsletter subscriptions.
Or use a .
Already registered? Login below.
